Various potential therapies that are projected to enter the schizophrenia market and give tough competition to CAPLYTA include Teva Pharmaceutical/MedinCell/Royalty Pharma's Olanzapine LAI (TEV-'749), Sunovion Pharmaceutical (Sumitomo Pharma)/Otsuka's Ulotaront (SEP-363856), Reviva Pharmaceuticals' Brilaroxazine (RP5063), Minerva Neurosciences/Mitsubishi Tanabe Pharma's Roluperidone (MIN-101/MT-210), Rovi Pharmaceuticals Laboratories' (Laboratorios Farmacéuticos Rovi) OKEDI/RISVAN (risperidone ISM), Neurocrine Biosciences/Mitsubishi Tanabe Pharma's Valbenazine (NBI-98854), Lyndra Therapeutics' LYN-005 (long-acting oral risperidone), and Newron Pharmaceuticals' Evenamide (NW-3509), among others.